PDS BIOTECHNOLOGY CORP (PDSB) Stock News

USA - Nasdaq - NASDAQ:PDSB - US70465T1079 - Common Stock

0.7554 USD

0 (-0.09%)

Last: 11/21/2025, 8:00:01 PM

0.7401 USD

-0.02 (-2.03%)

After Hours: 11/21/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PDSB Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill

News Image

PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Q3 2025 Earnings Beat, Stock Surges 64% in Pre-Market

10 days ago - By: PDS Biotechnology Corporation

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

12 days ago - By: Benzinga - Mentions: AIM STXS PRPH LUCY ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 days ago - By: PDS Biotechnology Corporation

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

13 days ago - By: PDS Biotechnology Corporation

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

17 days ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

24 days ago - By: Stocktwits

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

24 days ago - By: Stocktwits

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

25 days ago - By: PDS Biotechnology Corporation

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

2 months ago - By: PDS Biotechnology Corporation

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

3 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

3 months ago - By: The Motley Fool

PDSB Loss Improves as Costs Drop

3 months ago - By: PDS Biotechnology Corporation

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

3 months ago - By: Benzinga

Insights into PDS Biotechnology's Upcoming Earnings

4 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

6 months ago - By: Zacks Investment Research - Mentions: INTU ADP PWR FAST ...

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

6 months ago - By: Yahoo Finance - Mentions: IBRX COMM HD CAVA ...

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

6 months ago - By: PDS Biotechnology Corporation

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

7 months ago - By: PDS Biotechnology Corporation

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

7 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

8 months ago - By: PDS Biotechnology Corporation

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

8 months ago - By: Stocktwits - Mentions: VTI VXF

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

8 months ago - By: PDS Biotechnology Corporation

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update